Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1

Jonathan M. Shillingford, Klaus B. Piontek, Gregory G. Germino, Thomas Weimbs

Research output: Contribution to journalArticlepeer-review

Abstract

Aberrant activation of the mammalian target of rapamycin (mTOR) pathway occurs in polycystic kidney disease (PKD). mTOR inhibitors, such as rapamycin, are highly effective in several rodent models of PKD, but these models result from mutations in genes other than Pkd1 and Pkd2, which are the primary genes responsible for human autosomal dominant PKD. To address this limitation, we tested the efficacy of rapamycin in a mouse model that results from conditional inactivation of Pkd1. Mosaic deletion of Pkd1 resulted in PKD and replicated characteristic features of human PKD including aberrant mTOR activation, epithelial proliferation and apoptosis, and progressive fibrosis. Treatment with rapamycin was highly effective: It reduced cyst growth, preserved renal function, inhibited epithelial cell proliferation, increased apoptosis of cyst-lining cells, and inhibited fibrosis. These data provide in vivo evidence that rapamycin is effective in a human-orthologous mouse model of PKD.

Original languageEnglish (US)
Pages (from-to)489-497
Number of pages9
JournalJournal of the American Society of Nephrology
Volume21
Issue number3
DOIs
StatePublished - Mar 2010

ASJC Scopus subject areas

  • Nephrology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1'. Together they form a unique fingerprint.

Cite this